Frontiers in Neuroendocrinology · Nov 18, 2026
Melatonin, brain clearance, and dementia prevention: Revisiting the pineal-perivascular Axis
By Dabiry G, Mohamed D, Kumar KDS et al.
BACKGROUND: Melatonin has been proposed to support brain clearance of amyloid-β and tau, and its decline with age and in Alzheimer's disease has been interpreted as a contributor to clearance failure. The evidence underlying this proposal has not been appraised separately for endogenous pineal physiology and for administered melatonin. OBJECTIVE: To review the evidence relating melatonin to perivascular transport and brain clearance, and to assess what that evidence can support. METHODS: A critical narrative review. MEDLINE via PubMed, Scopus and the Cochrane Library were searched from inception to 31 August 2026, with an identical update search on 31 October 2026; database-specific strategies, dates, eligibility criteria and the selection process are reported in Section 3. Studies were appraised by what was manipulated (the organism's own pineal output, or administered melatonin at physiological or higher exposure, or actions not requiring receptor occupancy) and by the strength of design supporting each mechanistic claim. Animal doses were converted to human-equivalent doses by body-surface-area normalisation, with the method and its limitations stated in Section 3.6. The classification is applied in the tables; the text uses plain descriptions. FINDINGS: In the literature identified, no study manipulated endogenous pineal melatonin while measuring perivascular transport or clearance, and no study combined a melatonin receptor antagonist or receptor deletion with a clearance readout. A causal role for endogenous melatonin therefore remains untested. Positive preclinical findings used administered melatonin at exposures estimated to be two to four orders of magnitude above standard clinical dosing on a body-weight basis, and approximately 40 to 900 times standard dosing after body-surface-area normalisation, which limits their extension to routine supplementation. The timing of melatonin secretion relative to sleep-associated clearance differs between nocturnal rodents and diurnal humans, which constrains translation from rodent models. Human data are limited by the absence of a validated non-invasive measure of brain clearance. CONCLUSION: Available evidence is consistent with pharmacological modulation of components of the clearance system. Whether endogenous pineal melatonin regulates brain clearance has not been tested. Pinealectomy with timed replacement in a melatonin-proficient animal, and the addition of a receptor antagonist arm to existing designs, would address the principal gaps.
doi.org/10.1016/j.yfrne.2026.101301PubMed 43051465Interventions